pharma · HIV-1 Infection · HIV-1 infection
Gilead Sciences
Gilead Sciences Pty Limited
NovaPharmaNews editorial coverage mentioning Gilead Sciences — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- 333 Lakeside Drive, Foster City, CA 94404, US
- Founded
- 1987
- Employees
- 14,602
- Programs
- 30
- Drugs
- 54
- Patents
- 0
News & analysis
NovaPharmaNews articles mentioning Gilead Sciences — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Gilead Sciences — regulatory, clinical, and market analysis.
KRX IR Reference : Executive Summary Plan for SCD NDR (ENG, Jun 2026)
This page should frame the KRX English IR reference as a company disclosure/investor-relations document and give readers a concise way to navigate its purpose and likely themes. Keep the summary factual and avoid adding performance or product claims not present in the source.
Lilly and Gilead Drive Pharma M&A Surge: A Strategic Market Analysis
Eli Lilly and Gilead Sciences are at the forefront of a significant surge in pharmaceutical M&A activity, signaling a strategic shift towards targeted innovation. This analysis explores the drivers and implications of this trend for industry stakeholders.
ESMO 2025 Preview: Astra and Daiichi vs. Gilead
As ESMO 2025 approaches, Astra and Daiichi are positioning themselves against Gilead. This article analyzes the implications for investors and pharma teams.